Quarterly report pursuant to Section 13 or 15(d)

Collaboration Agreement (Details)

v3.19.2
Collaboration Agreement (Details)
6 Months Ended
Jun. 30, 2019
USD ($)
Upfront payment $ 3,000,000
Deferred revenue 1,500,000
Amount due 1,500,000
Fixed consideration 3,000,000
RX-3117 Development [Member]  
Upfront payment 2,500,000
RX-3117 Clinical Material [Member]  
Upfront payment 500,000
China [Member]  
Milestone payment 126,000,000
Republic of Singapore, China, Hong Kong, Macau and Taiwan [Member]  
Milestone payment $ 100,000,000